MAP Seeks $52M, Prepares to Resubmit Levadex NDA

MAP Pharmaceuticals Inc. priced an underwritten public offering of 3.9 million shares of its common stock at $13.40 apiece, seeking to raise $52 million as the biotech prepares to resubmit the new drug application (NDA) for Levadex, its inhalation aerosol for the acute treatment of migraine.